Archives of Gynecology and Obstetrics

, Volume 280, Issue 1, pp 149–152

Secondary involvement of the breast in T-cell non-Hodgkin lymphoma, an unusual example mimicking inflammatory breast carcinoma

  • Canan Kelten
  • Sibel Kabukcu
  • Nilay Sen
  • Zafer Teke
  • Arzu Yaren
  • Ergun Erdem
  • Ender Duzcan
Case Report


Non-Hodgkin lymphoma of the breast is a rare malignancy and present with almost equal frequency either as a primary or a secondary disease. Survival is poor in most cases of secondary breast lymphoma because of their advanced stage. We report a 35-year-old woman presenting with dyspnea as well as swelling, tenderness, and ruddiness in the left breast with non-cyclic pain for several months and maculopapular skin eruption in the same breast. Physical examination revealed fixed lymphadenopathies in both axillary regions. Radiologic evaluations (bilateral mammaograpy and ultrasonography) showed skin thickening in the left breast, asymmetrical densities in both breasts, and confirmed lymphadenopathies in the axillary regions. Excisional biopsies were performed to the left axillary lymph nodes and the breast skin eruptions. The histologic and immunohistochemical features were diagnosed as an ALK (−) anaplastic large cell lymphoma. A Computed Tomography examination was performed for staging the lymphoma and then chemotherapy was started. Thirty months after the diagnosis, the patient is still alive with disease. Because of the presence of systemic symptoms such as skin involvement and generalized lymphadenopathies (mediastinal, axillary or cervical), T cell lymphoma cases with breast involvement could mimic the clinical presentation of inflammatory breast carcinoma. Pathologic examination is needed for the correct diagnosis.


Lymphoma Lymphadenopathy Breast involvement Skin 


  1. 1.
    Domchek SM, Hecht JL, Fleming MD et al (2002) Lymphomas of the breast: primary and secondary involvement. Cancer 94(1):6–13PubMedCrossRefGoogle Scholar
  2. 2.
    Duncan VE, Reddy VV, Jhala NC et al (2006) Non-Hodgkin’s lymphoma of the breast: a review of 18 primary and secondary cases. Ann Diagn Pathol 10(3):144–148. doi:10.1016/j.anndiagpath.2005.09.018 PubMedCrossRefGoogle Scholar
  3. 3.
    Kuper-Hommel MJ, Snijder S, Janssen-Heijnen ML et al (2003) Treatment and survival of 38 female breast lymphomas: a population-based study with clinical and pathological reviews. Ann Hematol 82(7):397–404. doi:10.1007/s00277-003-0664-7 PubMedCrossRefGoogle Scholar
  4. 4.
    Loughrey MB, Windrum P, Catherwood MA et al (2004) WHO reclassification of breast lymphomas. J Clin Pathol 57(11):1213–1214. doi:10.1136/jcp.2004.018994 PubMedCrossRefGoogle Scholar
  5. 5.
    Topalovski M, Crisan D, Mattson JC (1999) Lymphoma of the breast. A clinicopathologic study of primary and secondary cases. Arch Pathol Lab Med 123(12):1208–1218PubMedGoogle Scholar
  6. 6.
    Jaffe ES (2006) Pathobiology of peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program 317–322. doi:10.1182/asheducation-2006.1.317
  7. 7.
    Fritzsche FR, Pahl S, Petersen I et al (2006) Anaplastic large-cell non-Hodgkin’s lymphoma of the breast in periprosthetic localisation 32 years after treatment for primary breast cancer, a case report. Virchows Arch 449(5):561–564. doi:10.1007/s00428-006-0287-1 PubMedCrossRefGoogle Scholar
  8. 8.
    Yumuk PF, Aydiner A, Topuz E et al (2004) T-cell lymphoblastic lymphoma presenting with a breast mass. Leuk Lymphoma 45(4):833–836. doi:10.1080/10428190310001617277 PubMedCrossRefGoogle Scholar
  9. 9.
    Mann KP, Hall B, Kamino H et al (1995) Neutrophil-rich, Ki-1-positive anaplastic large-cell malignant lymphoma. Am J Surg Pathol 19(4):407–416. doi:10.1097/00000478-199504000-00002 PubMedCrossRefGoogle Scholar
  10. 10.
    Fraulini C, Mauro E, Rigolin GM et al (2005) A case of advanced Hodgkin lymphoma with breast involvement treated with a combination of gemcitabine and pegylated liposomal. Eur J Haematol 75(6):515–517. doi:10.1111/j.1600-0609.2005.00558.x PubMedCrossRefGoogle Scholar
  11. 11.
    Press GA, Glazer HS, Wasserman TH et al (1985) Thoracic wall involvement by Hodgkin disease and non-Hodgkin lymphoma: CT evaluation. Radiology 157(1):195–198PubMedGoogle Scholar
  12. 12.
    McCluggage WG, Walsh MY, Bharucha H (1998) Anaplastic large cell malignant lymphoma with extensive eosinophilic or neutrophilic infiltration. Histopathology 32(2):110–115. doi:10.1046/j.1365-2559.1998.00335.x PubMedCrossRefGoogle Scholar
  13. 13.
    ten Berge RL, Oudejans JJ, Ossenkoppele GJ et al (2003) ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects, a review. J Pathol 200(1):4–15. doi:10.1002/path.1331 PubMedCrossRefGoogle Scholar
  14. 14.
    ten Berge RL, Oudejans JJ, Ossenkoppele GJ et al (2000) ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination. J Clin Pathol 53(6):445–450. doi:10.1136/jcp.53.6.445 PubMedCrossRefGoogle Scholar
  15. 15.
    Escalón MP, Liu NS, Yang Y et al (2005) Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson cancer center experience. Cancer 103(10):2091–2098. doi:10.1002/cncr.20999 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Canan Kelten
    • 1
  • Sibel Kabukcu
    • 2
  • Nilay Sen
    • 1
  • Zafer Teke
    • 3
  • Arzu Yaren
    • 4
  • Ergun Erdem
    • 3
  • Ender Duzcan
    • 1
  1. 1.Department of PathologyPamukkale University School of MedicineDenizliTurkey
  2. 2.Department of HematologyPamukkale University School of MedicineDenizliTurkey
  3. 3.Department of General SurgeryPamukkale University School of MedicineDenizliTurkey
  4. 4.Department of Medical OncologyPamukkale University School of MedicineDenizliTurkey

Personalised recommendations